Treatment Options for Dry AMD in Canada

Direct Answer

There is no single treatment option for dry age-related macular degeneration (AMD) that applies to every Canadian patient. The most appropriate approach depends on the individual’s disease stage, rate of progression, current visual function, and overall health. What is suitable for a patient with early dry AMD may differ significantly from what is appropriate for someone with more advanced disease.¹

For most Canadians with dry AMD, a management plan will include some combination of regular monitoring, lifestyle adjustments, and, where clinically appropriate, nutritional supplementation. For patients at intermediate or more advanced stages, device-based therapy may also be worth discussing. MacuMira is a Health Canada–authorized treatment device indicated to improve visual function in appropriate patients with dry AMD, supported by a published clinical trial. The right combination of approaches for any individual is best determined in consultation with a qualified eye care provider.²

How to Think About Dry AMD Treatment Options in Canada

Dry AMD is a chronic, progressive condition. Unlike wet AMD, which involves abnormal blood vessel growth and is treated with injections, dry AMD progresses more gradually, and its management has historically been less interventional. That picture is changing as more options become available, but the range of appropriate choices still varies significantly depending on where a patient is in the course of their disease.¹

The question of which treatment is “best” is also shaped by what the patient hopes to achieve. Some patients want to reduce the risk of their condition advancing. Others want to know whether anything can be done to improve how they see today. These are related, but distinct goals, and the options that address each goal differ. A good care conversation covers both.

Routine Monitoring: Still the Foundation

Regular eye examinations remain the cornerstone of dry AMD management at every stage of the disease. Monitoring allows an eye care provider to track structural changes in the retina over time, detect early signs of progression toward geographic atrophy or conversion to wet AMD, and adjust the care plan accordingly. For patients with early dry AMD who have not yet reached the stage where other interventions are indicated, monitoring is not passive or inadequate care. It is the clinically appropriate response to where they are in the disease course.¹

How often monitoring appointments are needed depends on disease stage and individual factors. Many patients with intermediate or advanced dry AMD are seen every 6 months. Patients at earlier stages may be monitored annually. Between appointments, Amsler grid self-monitoring at home helps patients detect changes in central vision that warrant earlier contact with their provider.

Lifestyle Modifications: Low Cost, Real Benefit

Modifiable lifestyle factors are consistently associated with AMD risk and progression. Stopping smoking is the most significant lifestyle intervention available to AMD patients; smokers have substantially higher rates of AMD progression than non-smokers. A diet rich in leafy green vegetables, yellow and orange produce, and fish is associated with a lower risk of AMD. UV-protective eyewear reduces cumulative retinal light exposure. Managing cardiovascular conditions such as high blood pressure also appears relevant to AMD risk.³

These recommendations apply at every stage of dry AMD and require no prescription, no referral, and no out-of-pocket cost beyond dietary choices. They are often underemphasized in clinical conversations because they are not dramatic interventions, but their cumulative impact over years is meaningful. Patients who make these changes alongside other treatments are likely to get more out of their overall care plan.

AREDS2 Supplementation

The AREDS2 formula, a combination of lutein, zeaxanthin, vitamin C, vitamin E, and zinc, was studied in a large National Eye Institute-funded clinical trial. The research showed that AREDS2 supplementation reduced the risk of progression to advanced AMD by approximately 25% in patients with intermediate dry AMD or advanced AMD in one eye. This is meaningful evidence for a specific patient population.⁴

AREDS2 supplementation is not recommended for patients with early dry AMD, where the progression risk is lower, and the evidence for benefit is less clear. It is also not a treatment that improves visual acuity or contrast sensitivity. Its role is in reducing progression risk, not in recovering lost function. Patients should have their AMD stage confirmed before starting supplementation, and a clinician should confirm whether the specific AREDS2 formulation is appropriate given the patient’s health history and other medications.⁴

Device-Based Therapy: An Option for Appropriate Patients

Device-based therapy for dry AMD has become a more relevant part of the management conversation as authorized options have emerged. MacuMira is a Health Canada–authorized treatment device indicated for use in Canada to improve visual function in patients with dry AMD. It delivers low-level electrical stimulation in a noninvasive clinical setting, under the supervision of an eye care professional.²

In its published clinical trial, patients in the treatment group achieved improvements in both visual acuity and contrast sensitivity. The trial used a randomized, sham-controlled design with validated outcome measures. Since launch, MacuMira has been used in hundreds of clinics across Canada and internationally, with a consistent safety record.²

Device-based therapy is not appropriate for every dry AMD patient. Eligibility depends on AMD stage, visual acuity, and a clinical assessment by a qualified provider. Patients with wet AMD are not candidates. Patients with baseline acuity better than 20/50 may experience different outcomes than those studied in the trial due to measurement ceiling effects. As with any treatment, honest discussion of what is and is not realistic for an individual patient is an essential part of the pre-treatment conversation.²

Device-based therapy is best understood as one component of a broader management plan rather than a standalone solution. Patients who begin device treatment should continue their routine monitoring and maintain any other clinically appropriate elements of their care plan.

Low Vision Support: Often Overlooked, Genuinely Important

For patients who have already experienced significant vision loss, low vision rehabilitation can meaningfully improve quality of life. Low vision specialists and occupational therapists work with patients to optimize the use of remaining vision through magnification devices, improved lighting, contrast-enhancing strategies, and training in adaptive techniques for daily tasks such as reading, cooking, and navigating unfamiliar environments.¹

Low vision support does not treat dry AMD, but it addresses its consequences. Patients who feel that managing the disease has not kept pace with their functional needs should ask their eye care provider for a referral to a low vision specialist. This step is often delayed longer than it needs to be.

Matching the Treatment to the Patient

Across all of these options, the common thread is that the “best” treatment is the one most suited to where a specific patient is in their disease course and what they are trying to achieve. A framework for thinking through the options:

1. If the goal is to reduce progression risk in intermediate or advanced dry AMD, AREDS2 supplementation, when clinically appropriate, has the strongest published evidence for this specific goal.⁴
2. If the goal is to improve current visual function, device-based therapy with MacuMira may be appropriate for eligible patients with dry AMD whose visual acuity falls within the range studied in the clinical trial.²
3. If significant vision loss has already occurred, low vision rehabilitation can help patients maintain independence and adapt to their changed visual capacity.
4. At all stages, routine monitoring, lifestyle modification, and open communication with an eye care provider form the foundation on which every other option builds.¹

None of these options is mutually exclusive. A patient receiving device-based therapy can and should also follow lifestyle recommendations, take AREDS2 if eligible, and attend regular monitoring appointments. The best outcome typically comes from addressing all relevant dimensions of the disease, not from finding a single solution.

What to Ask Your Eye Care Provider

• What stage of dry AMD do I have and what is my risk of progression?
• Am I a candidate for AREDS2 supplementation based on my AMD stage and health history?⁴
• Is device-based therapy something I should discuss and do I meet the eligibility criteria?²
• What lifestyle changes would have the most impact for someone at my stage of disease?
• Would a referral to a low vision specialist be appropriate given my current level of visual function?
• How often should I be monitored and what should I watch for between appointments?
• How will we know if my current management plan is working and when would we consider adjusting it?

Key Takeaway

The “best” treatment for dry AMD in Canada is the combination most suited to an individual patient’s stage of disease, progression risk, and functional goals. For most patients, this means a plan that includes monitoring, lifestyle modification, and AREDS2 supplementation when clinically appropriate. For eligible patients who want to address visual function, device-based therapy is now an authorized option in Canada. No single treatment replaces a thorough, individualized conversation with a qualified eye care provider.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Patients should speak with a qualified eye care professional to determine which treatment options are appropriate for their specific condition and health history.

Glossary

Dry AMD (dry age-related macular degeneration): A progressive retinal condition in which the macula gradually deteriorates, affecting central vision. The most common form of AMD. Managed through a combination of monitoring, lifestyle changes, supplementation and device-based therapy for appropriate patients.

Geographic atrophy: An advanced stage of dry AMD in which areas of the retinal pigment epithelium and photoreceptors break down, causing irreversible central vision loss. Detection and monitoring require retinal imaging.

AREDS2 formula: A nutritional supplement combination studied in the Age-Related Eye Disease Study 2. Includes lutein, zeaxanthin, vitamin C, vitamin E and zinc. Associated with approximately a 25% reduced risk of progression to advanced AMD in eligible patients.

MacuMira: A Health Canada–authorized treatment device indicated to improve visual function in patients with dry AMD. Noninvasive, delivers low-level electrical stimulation. For use under the supervision of an eye care professional. Not indicated for wet AMD.

Visual acuity: The clarity and sharpness of vision. Measured on standardized charts and expressed in Snellen notation (e.g., 20/50) or ETDRS letter score.

Contrast sensitivity: The ability to distinguish objects from their background at varying levels of contrast. Often reduced in dry AMD and captures functional deficits that standard acuity testing may miss.

Low vision rehabilitation: Specialized support for patients with significant vision loss. Includes training with magnification devices, adaptive lighting strategies and techniques for maintaining independence in daily activities.

Amsler grid: A grid-based self-monitoring tool used by AMD patients at home to detect changes in central vision, such as distortion or missing areas, between clinical appointments.

Wet AMD: A form of AMD in which abnormal blood vessels grow beneath the retina, causing more rapid vision loss than dry AMD. Treated with anti-VEGF injections. A distinct condition from dry AMD.

References

1. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.

2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.

3. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.

4. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847.

5. Age-Related Macular Degeneration (AMD). Canadian Ophthalmological Society. Date not listed. Accessed June 2026. https://www.seethepossibilities.ca/eye-health/age-related-macular-degeneration/.